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Abstract In present study, the potential drug delivery of
nanoformulations was validated via the comparison of
cellular uptake of nanoparticles in various cell lines and
in vivo pulmonary cellular uptake in intratracheally (IT)
dosed rat model. Nanoparticles were prepared by a bench
scale wet milling device and incubated with a series of cell
lines, including Caco-2, RAW, MDCK and MDCK trans-
fected MDR1 cells. IT dosed rats were examined for the
pulmonary cellular uptake of nanoparticles. The processes
of nanoparticle preparation did not alter the crystalline state
of the material. The uptake of nanoparticles was observed
most extensively in RAW cells and the least in Caco-2
cells. Efﬂux transporter P-gp did not prevent cell from
nanoparticles uptake. The cellular uptake of nanoparticles
was also conﬁrmed in bronchoalveolar lavage (BAL) ﬂuid
cells and in bronchiolar epithelial cells, type II alveolar
epithelial cells in the intratracheally administrated rats. The
nanoparticles uptake in MDCK, RAW cells and in vivo
lung epithelial cells indicated the potential applications of
nanoformulation for poorly soluble compounds. The
observed limited direct uptake of nanoparticles in Caco-2
cells suggests that the improvement in oral bioavailability
by particle size reduction is via increased dissolution rate
rather than direct uptake.
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Abbreviations
MDCK Madin-Darby canine kidney epithelial cell
RAW cell The murine macrophage-like cell lines
Caco-2 Human colon adenocarcinoma cell
BAL Bronchoalveolar lavage
Introduction
In association with slow dissolution characteristics, poor
permeability and/or the involvement of efﬂux transporters,
poorly aqueous soluble/permeable drugs present a chal-
lenging problem for drug formulation development due to
the limitation of drug absorption in the gastrointestinal (GI)
tract. In an environment of ever increasing drug entities
with these characteristics where conventional formulation
techniques are not efﬁcient to develop poorly water-soluble
compounds into drug products [1], novel approaches to
overcome these factors are of great importance. Among the
various solubility/dissolution rate enhancement methodol-
ogies available, particle size reduction is most commonly
employed by formulators to improve bioavailability.
Particle size reduction leads to increased dissolution and
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availability as outlined by the Ostwald-Feundlich equations
[2]. In addition, size reduction to the nanometer range of
10–1000 nm, termed nanoparticles [3], has been shown to
greatly improve exposure [4]. An outstanding feature of
nanoparticles is the greater surface area consequently
resulting in the increase in saturation solubility and the
increase in dissolution rate of the compounds. Recently,
nanoparticles have been reported to cross the intestinal
epithelial barrier or rapidly diffuse from the lungs into the
systemic circulation [5, 6]; however, the route, mechanism
and extents to which this occurs are not yet entirely clear.
The pharmaceutical industry has invested heavily in the
area of non-invasive delivery systems for GI poorly
absorbed or unstable molecules. One of the most important
aspects of systemic or local drug delivery routes has been
targeting drug delivery into the lungs. Accordingly, tech-
niques and new drug delivery devices intended to deliver
drugs into the lungs have been widely developed in the last
few years. Cellular uptake studies have demonstrated that
besides macrophages, other cell lines like cancer cells and
epithelial cells are also able to take up nanoparticles [7–9].
A hypothesis, which has not been widely investigated so
far, is that the variations of nanoparticles uptake in vivo are
observed in different tissue or cell barriers. To elucidate the
hypothesis, in this study, we investigated the uptakes and
transport of water-insoluble nanoparticles in various cell
lines and in a nanoparticle IT injected rat model.
Materials and Methods
Nanoparticle Formulation
For particle size reduction, a bench scale wet milling
(micronization) device was used [10]. To make the stock
nanosuspension formulation (20 mg/mL) pyrene (GC
grade from Fluka Chemical, Switzerland) or charcoal (acid
washed with hydrochloric acid, cell culture tested, Sigma-
Aldrich), an appropriate amount of glass beads, and 0.1%
(w/w) Tween 80 in phosphate buffered saline (pH 7.4)
were added in a scintillation vial. The mixture was then
stirred at 1200 rpm for a period of 48 h with occasional
shaking. The stock formulation was harvested and the
potency of suspension and supernatant were examined by
HPLC/UV.
Evaluation of Solid State Properties
Powder X-ray diffraction (PXRD) was used to conﬁrm the
solid state properties pre- and post-milling of pyrene, and
conducted with a Bruker D-8 Advance diffractometer. The
system used a copper X-ray source maintained at 40 kV
and 40 mA to provide radiation with intensity weighted
average of 1.54184 A ˚ (Kaave). A scintillation counter was
used for detection. Data were collected using a step scan of
0.02 per point with a 1 s/point counting time over a range
of 3–35 two-theta. In-house fabricated aluminum inserts
or inserts with a Hasteloy sintered ﬁlter (0.45 lm) pressed
in the center and held in Bruker plastic sample cup holders
were utilized for all analyses. Dry pyrene was run as
received without hand grinding. Suspensions were ﬁltered
onto sintered ﬁlters under vacuum. Particle size distribution
was determined on a Beckman Coulter LS 230 particle size
analyzer using a small volume accessory. Distributions
from 2000 lm to 0.04 lm were generated using Mie
scattering theory and a polarization intensity differential
scattering obscuration optical model (PIDS) with sample
obscurations held between 45% and 55%. There was no
absorption by pyrene at the scattering wavelengths so the
average index of refraction was determined by optical
microscopy using index matching ﬂuids (Cargille catalog
#18005).
Cell Culture
Caco-2 cells (Pﬁzer Global batch) were maintained in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supple-
mented with 10% fetal bovine serum, 1% non-essential
amino acids, 1% Glutamax, 1 mM sodium pyruvate, and
0.06 mg/mL Gentamicin. MDCK and MDCK-MDR1 cells
were cultured in minimum essential medium (MEM) with
Earle’s salts and L-glutamine containing 10% fetal bovine
serum (FBS), 100 units penicillin, and 100 lg/mL strep-
tomycin. The murine macrophage-like cells (RAW cells,
ATCC TIB 71) were cultured in DMEM supplemented
with 4 mM L-glutamine and 10% (v/v) FBS. All media and
reagents were obtained from the Gibco BRL (Carlsbad,
CA).
Cells were seeded at a density of 1 9 10
6 cells/mL in a
glass chamber slide (Nalge Nunc International, NY) with
regular changes in media. The uptake experiments were
conducted after cell reaching conﬂuence in a chamber
slide. For nanoparticle uptake, the cells were washed with
fresh medium and medium was replaced with nanoparticle
suspension (0.05 mg/mL). The cells then were incubated at
37 C in a humidiﬁed 5% CO2/95% air atmosphere. At 2
and 4 h post-incubation, the glass slide chambers were
completely washed with HBSS buffer to remove the non-
speciﬁc binding particles. The cells were ﬁxed with either
10% paraformaldehyde (for Pyrene nanoparticles) for
30 min or the ﬁxative from the Diff-Quik staining kits (for
charcoal nanoparticles). The ﬁxed cells were stained with
the Diff-Quik following the manufacturer’s instruction
(Dade Behring Inc, DE). Microscopic analysis was con-
ducted on a Nikon E600 polarizing microscope equipped
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polarization.
Intratracheally Instilled Nanoparticles
Male Sprague Dawley (SD) rats (*350–400 g) from
Charles Rivers Labs were anesthetized with 4–5% Isoﬂu-
rane anesthesia for oro-tracheal administration of 0.5%
Tween 80 vehicle and nano-suspension (4 mg/rat). The rats
were positioned to allow visualization of their vocal cords
and trachea using an otoscope. A Hamilton syringe was
used to inject 100 lL of pyrene nanosuspension directly
into the trachea. At 30 min and 120 min after oro-tracheal
dosing, rats were euthanized with 30 mg/kg pentobarbitol
(Sleepaway) injection intraperitoneally. The throat was
incised exposing the trachea and a cannula inserted for
bronchoalveolar lavage (BAL). BAL ﬂuid collection was
performed through four instillations of 2.5 mL each,
10 mL in total. After each BAL was recovered, the ﬂuid
was placed in a 15 mL conical tube on ice. The BAL ﬂuid
was centrifuged at 900g for 15 min at 4 C to precipitate
the cells. After being placed on glass slides, the cells were
ﬁxed with 10% paraformaldehyde for 30 min and then
stained with the Diff-Quik kit. A similar protocol was
conducted for charcoal nanoparticles and was followed by
the histopathological examination. The Pﬁzer Institutional
Animal Care and Use Committee (IACUC) reviewed and
approved the animal use in these studies. The Association
for Assessment and Accreditation of Laboratory Animal
Care, International fully accredits the Pﬁzer animal care
and use program.
Histopathology
At necropsy, the entire lung pluck with trachea was
removed. Lung lobes were instilled with approximately
10 mL of 10% neutral buffered formalin (NBF). The tra-
chea was clamped with a bull dog style clip to retain
instilled formalin throughout ﬁxation. Lungs were ﬁxed for
24 h in 10% NBF. Lung lobes were cassetted individually
to maintain identity and processed whole on a Sakura VIP
5 series by dehydrating through a series of graded ethanol
solutions, cleared with xylene and impregnated with par-
afﬁn. Lung lobes were embedded ventral aspect down in
block. Sections of 4 lm thickness were cut to expose
intrapulmonary airways for each lung lobe. Sectioned tis-
sues were heated in a 60 oven for a minimum of 1 h,
stained via automated linear stainer with hematoxylin–
eosin and coverslipped. The processed glass slides were
evaluated under Olympus light microscope and the images
were captured by Spot Insight Firewire Camera and ana-
lyzed by Spotsoftware Advanced (Diagnostic Instruments,
Inc., Sterling Heights, MI).
Results and Discussion
Wet Milling Preparation and the Solid State Properties
of Nanoparticles
Particle size reduction can be achieved by pressure, friction,
attrition impact, or shear. Milling technologies (wet or dry)
are well-established and convenient techniques for size
reduction [11]. Nanosuspensions are formed by building
particles during precipitation or breaking, as in milling, and
results innew formations that increase the total surface area.
During the milling process, more free energy is generated
and the system tends to agglomerate. However, this can be
mitigated by the addition of surfactants. Surfactant provides
a higher energy barrier to aggregation by changing the
interaction of the surface of the primary particles. In some
cases, electrostatic charges and amorphous domains on the
particle surface induced by the milling process, render the
ground material both cohesive and adhesive. These physical
and chemical changes caused by size reduction are highly
undesirable and can adversely affect the performance and
improvement in drug absorption. Low solubility and high
logP are recognized as two of the major challenges in the
drug discovery. Therefore, pyrene, which represents the
class of chemicals, was selected as a surrogate material to
test for the purpose. In contrast, charcoal, the absolute non-
soluble material resisting to the solvents during sample
preparing, was picked for understanding the intrinsic
behaviors of nano particles, and for the convenience of
imaging as well. In this experiment, we used a bench scale
wet milling device invented by Haskell [10], in which the
materials in the presence of surface stabilizers are commi-
nuted by milling media and the particle size reduction is
determined by the shear intensity and the number of contact
points. In our nanopreparations, the mean particle size for
all materials fell in between 0.3 and 0.6 lm following the
milling procedure; for pyrene, D25/D50/D90: 0.19/0.34/
0.68 lm; for charcoal, D25/D50/D75:0.15/0.25/0.44. Fur-
thermore, for the above reasons, the solid state properties of
pyrene were monitored both pre- and post-milling using
powder X-ray diffraction (PXRD). There were no obvious
form changes in the post-milled material (Fig. 1a). The
nanoparticle distribution in optical microscopy (Nikon
E600 pol) was shown in Fig. 1b. The results imply that the
wet milling process was an adequate technique for particle
size reduction for these highly crystalline small molecules
and should be highly relevant when considering drug par-
ticle stability in this system.
Nanoparticles Uptake in Epithelial Cell Lines
The oral bioavailability of a poorly absorbed molecule can
be improved by size reduction to the nanoparticle range.
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ment in bioavailability for HIV-1 protease inhibitors using
pH sensitive nanoparticles, as the smaller particle size can
increase surface area resulting in an increased dissolution
rate and bioavailability. Transmucosal passage of micro-
particles from the intestinal lumen to the systemic
circulation has been also observed [13]. In addition, by
reducing the size of particles to the sub-micron level,
enhanced uptake of intact polymeric particles was observed
in pre-clinical experiments [14, 15]. However, the relevant
importance and mechanism of directly cellular nanoparti-
cles uptake in overall improvement of drug absorption or
targeting delivery remains unclear.
The Caco-2 cell line, derived from human colorectal
carcinoma, spontaneously differentiates in culture to form
conﬂuent monolayers with remarkable morphological and
biochemical similarity to the small intestinal epithelium
[16]. Caco-2 cells have been developed as a useful alter-
native to animal models to study intestinal absorption of
therapeutic agents including proteins, peptides, and oligo-
nucleotides, showing promise that might give useful
predictions concerning the oral absorption potential [17–
19]. Therefore, the nanoparticles uptake studies observed
in Caco-2 cells could probably be considered to correlate
with in vivo situations. As shown in Fig. 2, both of char-
coal and pyrene nanoparticles were found in the cytoplasm
of the Caco-2 cells, though the nanoparticles in cytoplasm
of the Caco-2 cells were scattered (2–4 particles per scene)
up to a 4 h incubation period. The results suggest that the
uptake of intact nanoparticle by Caco-2 cells was limited.
This correlates with previously reported in vivo results that
the contribution of nanoparticles uptake on bioavailability
improvement of small molecules is limited, and the per-
centage of nanoparticles absorbed via the nanoparticles
transcytosis mechanism in the administrated dose is varied
ranged from 0.01 to 3.6% [6, 14, 20]. In contrast to our
observations, signiﬁcantly greater tissue uptake for biode-
gradable nanoparticles, such as polylactic-polyglycolic
acid co-polymer nanoparticles and lectin-coated nanopar-
ticles, have been observed. This variation in uptake has
important implications for designing nanoparticle-based
oral drug delivery systems, such as an oral vaccine system
[21–23]. Different from the crystallized small molecule in
absorption, these biodegradable particles, such as lectins
and invasins, can bind to the intestinal epithelial cells and
stimulate the uptake and transport of nanoparticles [9, 24–
26], suggesting the existence of carrier mediated transport
in intestinal epithelial cells or Caco-2 cells. Therefore, a
size-dependent transcytosis transport of biodegradable
particles in the gastrointestinal mucosal tissue might not be
Fig. 1 (a) The solid state properties of pyrene were monitored at pre-
and post-milling using powder X-ray diffraction (PXRD) in a Bruker
D-8 Advance diffractometer. Data were collected using a step scan of
0.02 per point with a one second/point counting time over a range of
3–35 two-theta. No changes of solid state properties of pyrene were
observed. (b) Distribution of nano pyrene. The image was taken on a
Nikon E600 polarizing microscope equipped with a Nikon DXM
1200 digital camera and ﬁlters for light polarization. Bar = 1 lm
Fig. 2 Nanoparticle uptake in
Caco-2 cells. The pyrene or
charcoal was applied in a
separated set of cells. (a) control
cells; (b) Caco-2 cell incubated
with charcoal nanoparticles for
4h ;( c) Caco-2 cells incubated
with pyrene nanoparticles for
4h
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123translatable to crystallized small molecules for the lack of
the nanoparticle carriers. In this study, the limited uptake of
nanoparticles in Caco-2 cells suggested that the transcy-
tosis transport of nanoparticles of small molecule directly
into systemic circulation might be not considered as a
major factor contributing to the improvement of drug
bioavailability. The fact that limited direct uptake of
nanoparticle in Caco-2 cells suggested that the improve-
ment of oral bioavailability [27] by the particle size
reduction is via increased dissolution rate rather than direct
uptake.
Recently, Madin-Darby Canine Kidney (MDCK) cells
have been an alternate model to Caco-2 cells for perme-
ability screening [28]. Similar to Caco-2 cells, MDCK cells
differentiate into columnar epithelium and form tight
junctions when cultured on semi-permeable membranes.
Primarily for passively absorbed compounds, the perme-
ability obtained from MDCK assays have been shown to be
similar to that from Caco-2 assays [29]. MDCK cells, like
the intact brain–blood barriers (BBB) (but unlike most
in vitro endothelial cell models), also have a transmem-
brane resistance but much lower than that in Caco-2 cells,
and thus the model is more relevant to assess passive dif-
fusion across the BBB. In a recent comprehensive
comparison of numerous in vitro models, MDCK cells
have been considered to offer the best model in terms of
predicting BBB penetration based on microdialysis data
[30]. When incubated with MDCK cells, nanoparticles
were found traversing though the cell membrane after 2 h
incubation. After 4 h incubation, the majority of nanopar-
ticles were located in the perinuclear region of the cells.
The nanoparticles entered the cells and were trapped inside
the cytoplasm but did not appear in the cell nucleus
(Fig. 3b). A greater extent of nanoparticle engulfment was
observed compared to that in Caco-2 cells. The results
suggested that signiﬁcant difference exists in nanoparticle
uptake among the different cell lines, which might reﬂect
the difference in translocation of nanoparticles in vivo.
We know that ATP binding cassette (ABC) transporters
are present in virtually every cell and they play a central
role in physiology. They may be pivotal in the protection of
against xenobiotics entering the organs or cells [31].
Moreover, multiple efﬂux transporters are identiﬁed in
Caco-2 cell and intestinal epithelial cells, and are respon-
sible for restricting intestine absorptions for their substrates
[32]. However, the effects of efﬂux transporter(s) on
nanoparticle uptake remain unknown. Recently, MDCK
cells genetically modiﬁed to overexpress human P-glyco-
protein (P-gp) have been shown to effectively discriminate
compounds that cross the BBB but are not P-gp substrates
from those that cross the BBB but are P-gp substrates. This,
along with the ability to assess P-gp transport, makes them
a very useful in vitro tool to assess the BBB permeation of
compounds and the extent of outwardly directed active
efﬂux [30]. In addition, the delivery of pulmonary drugs to
the site of action may also depend on the presence and
activity of many ABC transporters [33]. Even though there
is no direct evidence showing that efﬂux transporters might
prevent nanoparticles uptake from the cells, it would be of
further interest to investigate if the efﬂux mechanism on
the cells barriers (e.g. BBB or chemotherapy) could be
bypassed by using nanoparticles as a carrier system to
enhance uptake of the agents which are otherwise poorly
deposited because of the transporter mediated efﬂux [34].
To test the hypothesis, a similar experiment protocol was
applied to a MDCK-MDR1 cell that was genetically
engineered to overexpress P-gp. Not surprisingly, a similar
pattern of nanoparticle uptake was found in both the
MDCK and MDCK-MDR1 cells (Fig. 3). Signiﬁcant
MDCK and MDCK-MDR1 cell engulfment of nanoparti-
cles suggested that nanoformulation might be a useful tool
to overcome the BBB and/or efﬂux transporters in che-
motherapy via transcytosis mechanism.
Nanoparticles Uptake in Mouse Macrophage Cells
Despite the low percentage of uptake for orally adminis-
trated doses in GI tract, Clark et al. [35] reported that M-
cells in Peyer’s patches of the gastrointestinal lymphoid
tissues are involved the mechanisms in particulate pathway
of gastrointestinal absorption. Macrophage uptake, e.g.
Kuffer cells in liver, has also been reported to involve the
distribution of intravenously administered nanoparticles
[36]. To examine the nanoparticles uptake in monocytes,
Fig. 3 Uptake of Charcoal
nanoparticles in MDCK and
MDCK-MDR1 cells. (a) MDCK
cell; (b) MDCK cells incubated
with nanoparticles for 4 h; (c)
MDCK-MDR1 cells incubated
with nanoparticle for 4 h
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mouse macrophage RAW cells. Nanoparticles uptake by
RAW cell over 4 h time period was monitored by light
microscopy. These cells extensively took up the adminis-
tered nanoparticles through non-speciﬁc transcytosis. As
shown in Fig. 5, large amounts of nanoparticles were
engulfed into the cytoplasm of the RAW cells. Among the
cell lines tested, RAW cells had the greatest capability for
nanoparticles uptake for both pyrene (Fig. 4b) and charcoal
(Fig. 4c) among the cell lines tested. Our results indicated
that the extent of nanoparticles uptake into cells is
dependent upon the cell type and origin. These results not
only show that there are differences in nanoparticles uptake
in various cellular matrix, but also indicated that these
signiﬁcant differences in in vitro cell lines should be taken
into consideration and integrated into the design of nano-
particle formulation development.
Pulmonary Cellular Uptake of Nanoparticles
in Intratracheally Dosed Rat Model
Particle size and morphology have a pronounced effect on
all aspect of drug delivery to the lungs. Research has shown
that particles below 5 lm can be distributed deeply into the
Fig. 4 Nanoparticle uptake in
RAW cells: (a) control cell; (b)
incubation with charcoal
particles for 4 h; (c) incubation
with pyrene particles for 4 h
Fig. 5 Histopathological
images of nanoparticle inhaled
rat model (209). (a) Normal
terminal bronchi and alveoli
structures; (b) At 30 min post-
IT injections, the charcoal
particles attached to and/or
absorbed (arrow heads) by the
bronchial epithelium, alveolar
epithelium and residual
macrophages; (c) At 120 min
post-IT injections, the charcoal
particles distributed in
cytoplasm of macrophages, type
II alveolar epithelial cells and
bronchial epithelial cells (arrow
heads). The alveolar type I
epithelial cells are cuboidal and
hyperplastic. Most of the type II
alveolar cells had numerous
intracytoplasmic nanoparticles
and hypertophic
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123smaller airways, delaying the effect on phagocytic clear-
ance which can lead to longer action time [37]. Nemmar
et al. [5] reported that untraﬁne technetium (99mTC)
labeled carbon particles diffused, within 5 min, into the
systemic circulation, and concluded that in addition to the
particle translocation to the blood via phagocytosis by
macrophages and/or endocytosis by epithelial and endo-
thelial cells, other pathway(s) must also exist. We
hypothesize that direct transport of intact nanoparticles
through epithelial cell layers might also attribute to trans-
location of inhaled particles into the systemic circulation.
In our study, an intratracheal nanoparticles dosed rat model
was used to investigate nanoparticles translocation across
lung epithelial cells and nanoparticle phagocytosis in BAL
ﬂuid cells. For ease of detection and preventing the loss of
particle appearance during sample preparation, charcoal
nanoparticles were used in the rats for histopathological
sections. Post-necropsy, thin sections of lung were stained
with hematoxylin–eosin and then examined by light
microscopy. At 30 min and 2 h post-intratracheally injec-
tion, the lining tracheal epithelial cells of trachea, bronchi,
and bronchioli had various amount of the charcoal particles
deposited (Fig. 5b, c). Most deposited nanoparticles were
located at the terminal bronchioles and the surrounding
alveoli. Different from the epithelial surface retention
observed for micron-sized poly-styrene and glass particles
[38, 39], the alveolar cells and the alveolar macrophages
had charcoal particles on the surface as well as in the
cytoplasm (Fig. 5b). The deposits of charcoal particles on
the surface and intracytoplasm of endothelial cells and type
I epithelial cells (Fig. 5) were not obvious. At 30 min post-
injection, there were no morphological changes of the
alveolar epithelial cells and no evidence of inﬂammatory
inﬁltrations (Fig. 5b). However, at 2 h post-intratracheal
injection of nanoparticles, there were minimum inﬁltrations
of neutrophils. The alveolar epithelial cells, most likely
type II cells at the terminal bronchioles and its surrounding
alveoli became cuboidal, an indication of early cellular
activation (Fig. 5c). Our results reconﬁrmed with a number
of morphologic studies showing that nanoparticles pene-
trated into and beyond the epithelium rather rapidly. For
instance, uptake of nanoparticles in type I epithelial cells,
endothelial cells, and the alveolar septum of ultraﬁne gold-
particles was recently conﬁrmed by transmission electron
Fig. 6 Nanoparticle uptake in
cell from BAL ﬂuid: (a) the
uptakes of nanoparticle in BAL
cells at 30 min post-IT
injection, (b) the uptake of
nanoparticles in BAL cells at
120 min post-IT injection. (c, d)
BAL cells in control group at
30 min and 120 min post-IT
injections, respectively
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the evidences for uptake of ultraﬁne particles (nanoparti-
cles) in epithelial cells and in the interstitial spaces,
translocation into systemic circulation, and accumulation
in secondary target organs [41]. As mentioned above, we
administrated the water-insoluble charcoal nanoparticle;
therefore, the morphological change might be in agreement
with adaptive pulmonary responses to water non-soluble
charcoal nanoparticle. In fact, the signiﬁcant uptake of
inhaled nanoparticles were detected in the cells from BAL
ﬂuids (Fig. 6) as early as 30 min post-intratracheal injec-
tion of nanoparticles, and the damages in BAL cells were
also observed at 2 h post-dosing (Fig. 6). These early
responses might be the initial indications of granulomatous
reactions observed at the late stage [42]. This morphology
indicated that the intratracheal delivery of absolute water
non-soluble nanoparticles, at least in our case, may be the
cause of pulmonary granulomatous reaction at late stage.
However, this reaction should be considered to be inde-
pendent of the active drug components. Therefore, the
success of nanoformulation would probably depend on
chemophysiological properties of nanoparticles and toxi-
cological issues associated with understanding of the fate
of nanoparticles in vivo. The chronic implications of the
early inﬂammatory responses to the nanoparticles warrant
further investigation.
In conclusion, while the uptake of small molecule,
crystalline nanoparticles in caco-2 cells, which represents a
GI absorption model, was limited, a greater uptake was
observed in MDCK and MDCK cells overexpressing P-gp.
In addition, extensive uptake was observed in mouse
macrophage-like RAW cell, suggesting that nanoparticle
uptake is highly dependent on the cell type. The
improvement of oral bioavailability by particle size
reduction is via increased dissolution rate rather than direct
uptake; however, the approach of nanoparticle delivery
might further improve efﬁcacy and practicability of inhaled
delivery and/or to overcome efﬂux transporter barriers in
chemotherapy or CNS delivery.
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